Brenig Therapeutics to Present AI Designed NLRP3 Inhibitor at Keystone Symposia

June 23, 2026
Brenig Therapeutics will present new data on its AI designed brain-penetrant NLRP3 inhibitor BT-409 at the Keystone Symposia on Neuroinflammation in Health and Disease, showcasing how its Hybrid AI Platform supports CNS drug discovery.

Brenig Therapeutics will present new data on its brain-penetrant NLRP3 inhibitor program at the Keystone Symposia meeting, Neuroinflammation in Health and Disease, announced in a press release. The presentation, by Alexei Pushechnikov, PhD, will describe how the company used its Hybrid AI Platform to design BT-409, a small molecule targeting neuroinflammation in Parkinson's disease.

The Hybrid AI Platform combines physics-based structural biology with machine learning to optimize drug properties such as potency, selectivity, safety, and brain exposure in parallel. This approach aims to overcome challenges in developing therapies that can cross the blood-brain barrier while maintaining high target selectivity.

BT-409, discovered at Mwyngil Therapeutics and later acquired by Brenig, is now in early clinical studies. The company uses the same AI platform for its second clinical program, BT-267, a selective LRRK2 inhibitor for Parkinson's disease. Both programs demonstrate Brenig's method for designing small molecules with balanced pharmacologic profiles for central nervous system disorders.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

06/23
Insilico Medicine and SK Biopharmaceuticals Sign $2.5 Billion AI Drug Discovery Deal
06/23
ChemT Biotechnology Raises $4 Million Seed Round for AI in Biomanufacturing
06/23
Tredence Acquires KMK Consulting to Expand Healthcare and Life Sciences Business
06/23
DropGenie Raises Seed+ Round to Launch Miniaturized Gene Editing Platform
06/23
ChartSpan Acquires Validic to Expand Remote Patient Monitoring Platform

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You May Also Like